| Drug Name |
Saquinavir mesylate |
| Drug ID |
BADD_D01989 |
| Description |
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies.[A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] |
| Indications and Usage |
Saquinavir is indicated, in combination with ritonavir and other antiretroviral agents, for the treatment of HIV-1 infection in patients 16 years of age and older.[L3450] |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AE01 |
| DrugBank ID |
DB01232
|
| KEGG ID |
D01160
|
| MeSH ID |
D019258
|
| PubChem ID |
60934
|
| TTD Drug ID |
D0WI3T
|
| NDC Product Code |
0004-0244 |
| UNII |
UHB9Z3841A
|
| Synonyms |
Saquinavir | Saquinivir | Ro 31-8959 | Ro 31 8959 | Ro 318959 | Saquinavir Monomethanesulfonate | Monomethanesulfonate, Saquinavir | Saquinavir Mesylate | Invirase |
